{
  "event": {
    "ticker": "GSK",
    "company": "Nuvalent, Inc., a wholly owned subsidiary of GSK plc since 2026-07-15 (NUVL delisted; Royalty Pharma holds only a royalty interest)",
    "drug": "neladalkib (NVL-655)",
    "application_type": "NDA",
    "indication": "ALK-positive locally advanced or metastatic NSCLC previously treated with an ALK tyrosine kinase inhibitor (TKI pre-treated)",
    "pdufa_date": "2026-11-27"
  },
  "display": {
    "company": "GSK",
    "drug": "neladalkib",
    "indication_en": "ALK-positive lung cancer",
    "indication_zh": "ALK 阳性肺癌"
  },
  "probability_approval": 0.92,
  "confidence": "medium",
  "base_rate_used": 0.76,
  "key_factors": [
    {
      "factor": "Durable responses in a large, heavily pretreated single-arm cohort with no approved option after lorlatinib",
      "direction": "+",
      "step": "medium",
      "evidence": "ALKOVE-1 pivotal cohort (n=253 TKI-pretreated; 78% had at least 2 prior ALK TKIs; median 3 prior lines). ORR by blinded central review was 31% (95% CI 26-37), and 64% of responses lasted at least 12 months. Lorlatinib-pretreated patients (n=190): ORR 26%, median DOR 17.6 months. Lorlatinib-naive patients (n=63): ORR 46%. G1202R mutation: ORR 68%. Intracranial ORR was 32% overall and 63% in lorlatinib-naive patients. FDA Breakthrough Therapy designation is for patients after at least 2 ALK TKIs.",
      "source": "Nuvalent press release 2025-11-17; ASCO 2026 abstract 8503 (JCO 44:16_suppl); Nuvalent 10-Q filed 2026-05-07"
    },
    {
      "factor": "Same sponsor, same FDA division, same kind of evidence: zidesamtinib was approved early in July 2026",
      "direction": "+",
      "step": "medium",
      "evidence": "Nuvalent's ROS1 inhibitor zidesamtinib (Jideytro) was approved on 2026-07-22 on single-arm ARROS-1 data in TKI-pretreated ROS1+ NSCLC, almost two months before its 2026-09-18 PDUFA date. That shows the agency accepts this development model from this sponsor, and that Nuvalent's regulatory and CMC organization has already taken a product through FDA review. Single-arm approvals of targeted TKIs in resistant NSCLC are well established (for example, lorlatinib in 2018).",
      "source": "GSK 6-K Q2 2026 results (2026-07-28); ASCO Post 2026-07 approval report"
    },
    {
      "factor": "Breakthrough Therapy, Priority Review and no advisory committee announced",
      "direction": "+",
      "step": "small",
      "evidence": "The NDA was submitted in April 2026 and accepted 2026-05-27 with Priority Review and a PDUFA date of 2026-11-27. No ODAC meeting has been announced as of 2026-10-04. The product also has Orphan Drug designation.",
      "source": "Nuvalent 8-K 2026-04-07; Nuvalent press release 2026-05-27; Royalty Pharma 10-Q filed 2026-08-05"
    },
    {
      "factor": "GSK now owns the application",
      "direction": "+",
      "step": "small",
      "evidence": "GSK completed its $10.6B acquisition of Nuvalent on 2026-07-15. GSK lists the US regulatory decision for neladalkib as an H2 2026 event and expects a 2026 launch if approved. Big-pharma applications have a ~95%+ base rate, but this NDA was compiled by Nuvalent before the deal, so I count ownership as a step rather than switching the anchor.",
      "source": "Nuvalent 8-K 2026-07-15 (merger completion); GSK press release on completion; GSK 6-K Q2 2026"
    },
    {
      "factor": "Oral small molecule whose supply chain has already supported an FDA approval",
      "direction": "+",
      "step": "small",
      "evidence": "Nuvalent built its commercial-scale process through CMOs, and that network supported the zidesamtinib approval. The neladalkib-specific sites are not disclosed, so I cannot confirm overlap.",
      "source": "Nuvalent 10-Q filed 2026-05-07"
    },
    {
      "factor": "Liver-enzyme signal needs label management",
      "direction": "-",
      "step": "small",
      "evidence": "In the RP2D safety population (n=656), ALT increase occurred in 47% and AST increase in 44%. The company describes these as mostly low-grade, transient and reversible. Discontinuation for TEAEs was 5% and dose reduction 17%. This is likely to mean label monitoring rather than a barrier to approval.",
      "source": "Nuvalent press release 2025-11-17"
    },
    {
      "factor": "Some suppliers are in China",
      "direction": "-",
      "step": "small",
      "evidence": "Nuvalent's risk factors say some manufacturers and suppliers are located in China and cite the BIOSECURE law enacted in December 2025. That law limits federal procurement rather than FDA approval, and it did not stop zidesamtinib's approval.",
      "source": "Nuvalent 10-Q filed 2026-05-07 (risk factors)"
    },
    {
      "factor": "Single-arm evidence; pathway and confirmatory plan not stated",
      "direction": "-",
      "step": "small",
      "evidence": "The NDA rests on ORR and DOR from a Phase 1/2 trial. Whether accelerated or regular approval is sought has not been disclosed. If accelerated, the randomized Phase 3 ALKAZAR trial (neladalkib vs alectinib, TKI-naive) is enrolling and could serve as the confirmatory trial. The label could be narrower than 'TKI pre-treated', but that would still count as approval.",
      "source": "Nuvalent Q1 2026 results (8-K Ex.99.1, 2026-05-07); ClinicalTrials.gov NCT06765109"
    }
  ],
  "manufacturing_risk": {
    "level": "low",
    "why": "This is an oral small-molecule kinase inhibitor. Nuvalent's CMO network just supported FDA approval of its sister TKI zidesamtinib (July 2026), and GSK now owns the program. The residual risks are undisclosed site-level inspection outcomes and China-based suppliers named in the risk factors."
  },
  "what_would_change_my_mind": [
    "An ODAC being scheduled, or a PDUFA extension (major amendment)",
    "GSK disclosing label negotiations or an early approval (the zidesamtinib precedent suggests early action is possible)",
    "New hepatotoxicity findings, such as Hy's-law cases, in updated ALKOVE-1 safety data",
    "Any manufacturing or import issue affecting China-based suppliers"
  ],
  "summary_en": "We put approval in this review cycle at 92%, well above the ~76% base rate for small/mid-cap original NDAs. The FDA has a long record of approving targeted lung-cancer drugs on durable single-arm response data. ALKOVE-1 showed a 31% response rate in 253 heavily pretreated ALK-positive patients (26% after lorlatinib, where no approved option exists), with long responses and brain activity. The drug has Breakthrough designation and Priority Review. The same sponsor's zidesamtinib was approved two months early in July 2026. GSK, which completed its Nuvalent acquisition in July, now owns the application. The main risks are a liver-enzyme signal and undisclosed details of the manufacturing sites.",
  "summary_zh": "我们估计本轮审评获批概率为92%，远高于中小型公司原始NDA约76%的基准。FDA向来依据单臂试验中持久的缓解数据批准肺癌靶向药。ALKOVE-1研究中，253名经多线治疗的ALK阳性患者客观缓解率为31%，劳拉替尼治疗后患者为26%（目前该人群无获批药物），缓解持久且有颅内活性。该药获突破性疗法认定和优先审评；同一申办方的zidesamtinib已于2026年7月提前约两个月获批。GSK已于7月完成对Nuvalent的收购，现为申请持有方。主要风险是转氨酶升高信号，以及生产场地细节未公开。",
  "sources": [
    "https://www.sec.gov/Archives/edgar/data/1861560/000186156026000003/nuvl-20260407.htm (8-K 2026-04-07: NDA submitted)",
    "https://www.sec.gov/Archives/edgar/data/1861560/000186156026000020/nuvl-ex99_1.htm (8-K 2026-05-07: Q1 2026 update, ALKAZAR)",
    "https://www.sec.gov/Archives/edgar/data/1861560/000186156026000021/nuvl-20260331.htm (10-Q filed 2026-05-07: BTD, China suppliers, CMOs)",
    "https://investors.nuvalent.com/2026-05-27-Nuvalent-Announces-Key-Program-and-Business-Updates,-Strengthening-Foundation-for-Global-Leadership-in-ROS1-and-ALK-positive-NSCLC (NDA accepted, Priority Review, PDUFA 2026-11-27)",
    "https://investors.nuvalent.com/2025-11-17-Nuvalent-Announces-Positive-Topline-Pivotal-Data-from-ALKOVE-1-Clinical-Trial-of-Neladalkib-for-TKI-Pre-treated-Patients-with-Advanced-ALK-positive-NSCLC",
    "https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.8503 (ASCO 2026 ALKOVE-1 abstract)",
    "https://www.sec.gov/Archives/edgar/data/1861560/000119312526304126/d52896d8k.htm (8-K 2026-07-15: merger with GSK completed)",
    "https://www.gsk.com/en-gb/media/press-releases/gsk-completes-acquisition-of-nuvalent-inc/",
    "https://www.sec.gov/Archives/edgar/data/1131399/000165495426006949/a1493o.htm (GSK 6-K Q2 2026: neladalkib US regulatory decision H2 2026; Jideytro approved)",
    "https://ascopost.com/news/july-2026/fda-approves-zidesamtinib-for-second-line-treatment-of-ros1-positive-nsclc/",
    "https://www.targetedonc.com/view/fda-grants-priority-review-to-neladalkib-nda-for-alk-positive-nsclc",
    "Royalty Pharma 10-Q filed 2026-08-05 (royalty interest in neladalkib; PDUFA 2026-11-27)",
    "https://clinicaltrials.gov/study/NCT06765109 (ALKAZAR Phase 3)"
  ],
  "zh": {
    "indication": "既往接受过 ALK 酪氨酸激酶抑制剂（TKI）治疗（即 TKI 经治）的 ALK 阳性局部晚期或转移性非小细胞肺癌（NSCLC）",
    "key_factors": [
      {
        "factor": "在一个规模较大、经多线治疗的单臂队列中观察到持久缓解，而 lorlatinib 治疗后目前尚无获批选择",
        "evidence": "ALKOVE-1 关键队列（n=253 例 TKI 经治患者；78% 既往接受过至少 2 种 ALK TKI；既往治疗线数中位数为 3）。经盲态独立中心评估的客观缓解率（ORR）为 31%（95% CI 26-37），64% 的缓解持续至少 12 个月。Lorlatinib 经治患者（n=190）：ORR 26%，中位缓解持续时间（DOR）17.6 个月。Lorlatinib 初治患者（n=63）：ORR 46%。G1202R 突变患者：ORR 68%。颅内 ORR 总体为 32%，在 lorlatinib 初治患者中为 63%。FDA 突破性疗法认定针对既往接受过至少 2 种 ALK TKI 的患者。"
      },
      {
        "factor": "同一申办方、同一 FDA 审评部门、同类证据：zidesamtinib 已于 2026 年 7 月提前获批",
        "evidence": "Nuvalent 的 ROS1 抑制剂 zidesamtinib（Jideytro）基于单臂 ARROS-1 数据，于 2026 年 7 月 22 日获批用于 TKI 经治的 ROS1 阳性 NSCLC，比其 2026 年 9 月 18 日的 PDUFA 目标日期提前近两个月。这表明 FDA 认可该申办方的这一开发模式，也说明 Nuvalent 的注册和化学、生产与控制（CMC）团队已有完整走完 FDA 审评的经验。靶向 TKI 在耐药 NSCLC 中基于单臂数据获批已有充分先例（例如 2018 年的 lorlatinib）。"
      },
      {
        "factor": "突破性疗法认定、优先审评，且未宣布召开专家咨询委员会会议",
        "evidence": "新药申请（NDA）于 2026 年 4 月提交，2026 年 5 月 27 日获受理并获优先审评，PDUFA 目标日期为 2026 年 11 月 27 日。截至 2026 年 10 月 4 日，未宣布召开肿瘤药物咨询委员会（ODAC）会议。该产品还拥有孤儿药资格认定。"
      },
      {
        "factor": "GSK 现已成为该申请的持有方",
        "evidence": "GSK 于 2026 年 7 月 15 日完成以 106 亿美元收购 Nuvalent。GSK 将 neladalkib 的美国监管决定列为 2026 年下半年事件，并预计若获批将于 2026 年上市。大型药企申请的基准获批率约为 95% 以上，但本 NDA 是 Nuvalent 在交易前编制的，因此我将所有权变更计为一项上调因素，而非更换锚定基准。"
      },
      {
        "factor": "口服小分子，其供应链已支持过一次 FDA 批准",
        "evidence": "Nuvalent 通过合同生产商（CMO）建立了商业化规模工艺，该网络支持了 zidesamtinib 的获批。neladalkib 的具体生产场地未披露，因此我无法确认两者是否重叠。"
      },
      {
        "factor": "肝酶信号需要通过说明书加以管理",
        "evidence": "在推荐 2 期剂量（RP2D）安全性人群（n=656）中，ALT 升高发生率为 47%，AST 升高为 44%。公司称这些事件多为低级别、一过性且可逆。因治疗期间不良事件（TEAE）停药的比例为 5%，减量比例为 17%。这更可能意味着在说明书中加入监测要求，而非构成获批障碍。"
      },
      {
        "factor": "部分供应商位于中国",
        "evidence": "Nuvalent 的风险因素披露部分生产商和供应商位于中国，并提及 2025 年 12 月颁布的 BIOSECURE 法。该法限制的是联邦采购，而非 FDA 批准，也并未阻碍 zidesamtinib 获批。"
      },
      {
        "factor": "单臂证据；审批路径和确证计划尚未说明",
        "evidence": "该 NDA 以一项 1/2 期试验的 ORR 和 DOR 为依据。申请的是加速批准还是常规批准尚未披露。若为加速批准，正在入组的随机 3 期试验 ALKAZAR（neladalkib 对比 alectinib，TKI 初治）可作为确证性试验。获批适应症可能窄于“TKI 经治”，但这仍计为获批。"
      }
    ],
    "manufacturing_risk_why": "这是一款口服小分子激酶抑制剂。Nuvalent 的 CMO 网络刚刚支持其姊妹 TKI zidesamtinib 获得 FDA 批准（2026 年 7 月），且 GSK 现已拥有该项目。剩余风险在于未披露的场地层面检查结果，以及风险因素中提及的中国供应商。",
    "what_would_change_my_mind": [
      "安排召开 ODAC 会议，或 PDUFA 目标日期延期（重大修改）",
      "GSK 披露说明书谈判或提前获批（zidesamtinib 的先例表明可能提前作出决定）",
      "ALKOVE-1 更新安全性数据中出现新的肝毒性发现，例如符合 Hy's law 的病例",
      "任何影响中国供应商的生产或进口问题"
    ]
  },
  "recorded_at": "2026-10-04T19:58:13+00:00"
}